Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?-Reference-Cited by-同舟云学术

Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?

Published:2022-12-12 Issue:2 Volume:20 Page:116-123
ISSN:1759-4812
Container-title:Nature Reviews Urology
language:en
Short-container-title:Nat Rev Urol

Author:

Chen Kenneth,O’Brien Jonathan^ORCID,McVey Aoife,Jenjitranant Pocharapong,Kelly Brian D.,Kasivisvanathan Veeru,Lawrentschuk Nathan,Murphy Declan G.^ORCID,Azad Arun A.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

https://www.nature.com/articles/s41585-022-00669-z.pdf

Reference73 articles.

1. Giona, S. The Epidemiology of Prostate Cancer (Exon Publications, 2021).

2. Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).

3. James, N. D. et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur. Urol. 67, 1028–1038 (2015).

4. Tangen, C. M. et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J. Urol. 188, 1164–1169 (2012).

5. US Food and Drug Administration. Drug approval package — Taxotere (docetaxel) injection (FDA, 2004).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10;Cell Communication and Signaling;2024-09-03

2. Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer;International Journal of Molecular Sciences;2024-08-26

3. Cardio-oncology in advanced prostate cancer;Frontiers in Oncology;2024-06-14

4. Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide;FUTURE ONCOL;2024

5. NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10;2024-01-22